Dapagliflozin and blood sugar swings in people after weight-loss surgery
Tests dapagliflozin on blood sugar swings in adults after bariatric surgery.
Plain-language title generated from the registry record
Registry title: Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery
Key facts
- Where
- Kuwait City, KuwaitSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 70 years old?
Source: NCT07515391, who can take part
Where in Kuwait
- Dasman Diabetes InstituteKuwait City, KuwaitNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Dasman Diabetes Institute
- Trial code
- NCT07515391
- Record updated
- 7 April 2026
- Original description
This study evaluates the effect of SGLT-2 inhibitors (dapagliflozin) on the blood glucose excursions by a continuous glucose monitoring system, the incidence of hypoglycemia and hyperglycemia and change in glycated hemoglobin (HbA1c) level in people had bariatric surgery with and without type 2 diabetes.Read full original descriptionShow less
Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery
This study evaluates the effect of SGLT-2 inhibitors (dapagliflozin) on the blood glucose excursions by a continuous glucose monitoring system, the incidence of hypoglycemia and hyperglycemia and change in glycated hemoglobin (HbA1c) level in people had bariatric surgery with and without type 2 diabetes.
Inclusion: People diagnosed with type 2 diabetes prior to bariatric surgery; People did not have diabetes prior to bariatric surgery; Willing to participate in this study.
Exclusion: Patients using insulin therapy or a sulfonylurea; Type 1 diabetes; Secondary diabetes; History of ketoacidosis; History of pancreatitis and pancreatectomy; Uncontrolled hypertension; Uncontrolled thyroid disease; Any history of serious hypertension reaction to the dapagliflozin or SGLT-2 inhibitor; History of malignancy within 5-year of screening; Presence of any other medical condition that would in the opinion of the investigator, preclude safe participation in the study; History of primary renal glycosuria or hereditary glucose-galactose malabsorption; Active diabetes complications, nephropathy (dipstick positive proteinuria, or reduced eGFR (<60 ml/min), proliferative retinopathy; HbA1c >10.5; Clinically significant abnormal liver function test; Pregnant ladies, or intending pregnancy or breastfeeding; Unable to sign the consent form.